Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis

Background: Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC. M...

Full description

Saved in:
Bibliographic Details
Published inBiomarkers Vol. 28; no. 5; pp. 427 - 436
Main Authors Min, Liang, Chen, Jinghua, Yu, Meihong, Yang, Ke, Liu, Deliang
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 04.07.2023
Subjects
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Circulating Tumor DNA - genetics
Circulating tumour DNA
Disease-Free Survival
gastric cancer
Humans
liquid biopsy
meta-analysis
Prognosis
Stomach Neoplasms - diagnosis
Stomach Neoplasms - genetics
survival
meta-analysis
Circulating tumour DNA
gastric cancer
prognosis
liquid biopsy
survival
Online AccessGet full text

Cover

Abstract Background: Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC. Methods: PubMed, Web of Science and Cochrane databases were searched to identify studies reporting the use of ctDNA to predict GC outcome and all relevant studies published until November 2022 were enrolled for our analysis. Data were extracted by two authors independently and statistic analysis was conducted by R program with 'meta' and 'metafor' packages. Results: A total of 34 qualified articles with 5091 subjects were incorporated into our meta-analysis. The corresponding Hazard ratio (HR) of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 2.74 (95% CI:2.24-3.35), 3.13 (95% CI:2.08-4.72) and 3.04 (95% CI:2.46-3.76), respectively, in GC patients. Conclusion: Blood-based ctDNA assay would be a potential novel biomarker for GC evaluation and prediction. Simple Summary: This is the integrated meta-analysis on the association of circulating tumour DNA (ctDNA) and prognosis of gastric cancer (GC) with an increasing number of studies exploring the prognostic value of GC in the last few years, which depicted that the detection of ctDNA could be a promising predictor in GC patients.
AbstractList Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC. PubMed, Web of Science and Cochrane databases were searched to identify studies reporting the use of ctDNA to predict GC outcome and all relevant studies published until November 2022 were enrolled for our analysis. Data were extracted by two authors independently and statistic analysis was conducted by R program with 'meta' and 'metafor' packages. A total of 34 qualified articles with 5091 subjects were incorporated into our meta-analysis. The corresponding Hazard ratio (HR) of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 2.74 (95% CI:2.24-3.35), 3.13 (95% CI:2.08-4.72) and 3.04 (95% CI:2.46-3.76), respectively, in GC patients. Blood-based ctDNA assay would be a potential novel biomarker for GC evaluation and prediction. This is the integrated meta-analysis on the association of circulating tumour DNA (ctDNA) and prognosis of gastric cancer (GC) with an increasing number of studies exploring the prognostic value of GC in the last few years, which depicted that the detection of ctDNA could be a promising predictor in GC patients.
Background: Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC. Methods: PubMed, Web of Science and Cochrane databases were searched to identify studies reporting the use of ctDNA to predict GC outcome and all relevant studies published until November 2022 were enrolled for our analysis. Data were extracted by two authors independently and statistic analysis was conducted by R program with 'meta' and 'metafor' packages. Results: A total of 34 qualified articles with 5091 subjects were incorporated into our meta-analysis. The corresponding Hazard ratio (HR) of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 2.74 (95% CI:2.24-3.35), 3.13 (95% CI:2.08-4.72) and 3.04 (95% CI:2.46-3.76), respectively, in GC patients. Conclusion: Blood-based ctDNA assay would be a potential novel biomarker for GC evaluation and prediction. Simple Summary: This is the integrated meta-analysis on the association of circulating tumour DNA (ctDNA) and prognosis of gastric cancer (GC) with an increasing number of studies exploring the prognostic value of GC in the last few years, which depicted that the detection of ctDNA could be a promising predictor in GC patients.
Background: Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC.Methods: PubMed, Web of Science and Cochrane databases were searched to identify studies reporting the use of ctDNA to predict GC outcome and all relevant studies published until November 2022 were enrolled for our analysis. Data were extracted by two authors independently and statistic analysis was conducted by R program with 'meta' and 'metafor' packages.Results: A total of 34 qualified articles with 5091 subjects were incorporated into our meta-analysis. The corresponding Hazard ratio (HR) of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 2.74 (95% CI:2.24-3.35), 3.13 (95% CI:2.08-4.72) and 3.04 (95% CI:2.46-3.76), respectively, in GC patients.Conclusion: Blood-based ctDNA assay would be a potential novel biomarker for GC evaluation and prediction.Simple Summary: This is the integrated meta-analysis on the association of circulating tumour DNA (ctDNA) and prognosis of gastric cancer (GC) with an increasing number of studies exploring the prognostic value of GC in the last few years, which depicted that the detection of ctDNA could be a promising predictor in GC patients.Background: Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric cancer (GC) is still controversial. This systematic review and meta-analysis aimed to evaluate the prognostic value of ctDNA in GC.Methods: PubMed, Web of Science and Cochrane databases were searched to identify studies reporting the use of ctDNA to predict GC outcome and all relevant studies published until November 2022 were enrolled for our analysis. Data were extracted by two authors independently and statistic analysis was conducted by R program with 'meta' and 'metafor' packages.Results: A total of 34 qualified articles with 5091 subjects were incorporated into our meta-analysis. The corresponding Hazard ratio (HR) of overall survival (OS), disease-free survival (DFS) and progression-free survival (PFS) were 2.74 (95% CI:2.24-3.35), 3.13 (95% CI:2.08-4.72) and 3.04 (95% CI:2.46-3.76), respectively, in GC patients.Conclusion: Blood-based ctDNA assay would be a potential novel biomarker for GC evaluation and prediction.Simple Summary: This is the integrated meta-analysis on the association of circulating tumour DNA (ctDNA) and prognosis of gastric cancer (GC) with an increasing number of studies exploring the prognostic value of GC in the last few years, which depicted that the detection of ctDNA could be a promising predictor in GC patients.
Author Min, Liang
Liu, Deliang
Chen, Jinghua
Yu, Meihong
Yang, Ke
Author_xml – sequence: 1
  givenname: Liang
  surname: Min
  fullname: Min, Liang
  organization: Research Center of Digestive Disease, Central South University
– sequence: 2
  givenname: Jinghua
  surname: Chen
  fullname: Chen, Jinghua
  organization: Department of Oncology, the Third Xiangya Hospital, Central South University
– sequence: 3
  givenname: Meihong
  surname: Yu
  fullname: Yu, Meihong
  organization: Research Center of Digestive Disease, Central South University
– sequence: 4
  givenname: Ke
  surname: Yang
  fullname: Yang, Ke
  organization: Department of Neurology, the Third Xiangya Hospital, Central South University
– sequence: 5
  givenname: Deliang
  surname: Liu
  fullname: Liu, Deliang
  email: Deliangliu@csu.edu.cn
  organization: Research Center of Digestive Disease, Central South University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37036017$$D View this record in MEDLINE/PubMed
BookMark eNqFkE1r3DAQhkVJaD7an9DiYy_ejCzbstNLQ5qPQkguCfRSxFiWFgVZSiWZsv31kdlNDjm0J72I5x1mniOy57xThHyisKLQwQllTc0b-LmqoGKrqgLatvU7ckhZ25ZNB_Xekpu6XKADchTjIwBlVd-9JweMA2uB8kPy6yEZa_4aty6kCXK2mJac5snPofh-e1ZgLLB4Cn7tfExG5qhGI5MPhdfFGmMK-VOikyqcZnJSCUt0aDfRxA9kX6ON6uPuPSYPlxf359flzd3Vj_Ozm1LmbVM5QKWx6cexx5rCUFdDk_fTHHSvNG16YJKxgY9jp_jQdrxjqgM9doMcFMdasWPyZTs37_l7VjGJyUSprEWn_BxFxfue8nw7zejnHToPkxrFUzATho14UZKBZgvI4GMMSr8iFMSiXryoF4t6sVOfe1_f9KRJ2aZ3KaCx_21_27aN0z5M-McHO4qEG-uDDtmuiYL9e8QzAVudCg
CitedBy_id crossref_primary_10_1016_j_abb_2024_110066
crossref_primary_10_1186_s12935_024_03209_4
crossref_primary_10_1146_annurev_med_100223_090016
crossref_primary_10_3748_wjg_v30_i12_1680
Cites_doi 10.1158/1078-0432.CCR-18-1128
10.1016/j.aca.2020.02.006
10.1186/s12943-020-01274-7
10.1007/s10555-020-09925-3
10.1038/nmat4997
10.1002/cam4.2799
10.7326/0003-4819-158-4-201302190-00009
10.1136/bmj.327.7414.557
10.1016/S0140-6736(20)31288-5
10.1002/ijc.30018
10.1136/bmjgast-2019-000355
10.1002/jcla.23936
10.1158/1078-0432.CCR-21-1414
10.1016/j.annonc.2022.02.007
10.1136/bmj.n71
10.1259/bjr.20181044
10.7717/peerj.2112
10.1186/1471-230X-13-87
10.1177/1533033820973279
10.1001/jama.283.15.2008
10.1007/s10120-022-01313-w
10.1007/s10620-007-0135-4
10.1371/journal.pone.0067195
10.18632/oncotarget.14064
10.1007/s10238-010-0097-2
10.5230/jgc.2013.13.3.157
10.1136/bmj.b2535
10.5152/tjg.2021.20832
10.1371/journal.pone.0242145
10.1186/s12967-022-03567-5
10.1136/bmj.315.7109.629
10.1080/10408363.2019.1700902
10.1001/jama.2016.7914
10.1136/gutjnl-2020-322658
10.1007/s12253-019-00658-5
10.1002/jrsm.11
10.1038/s41419-020-2531-z
10.1038/s41467-020-14310-3
10.1007/s10620-013-3007-0
10.1158/1078-0432.CCR-19-1704
10.1038/s41416-020-1002-8
10.3390/genes10110926
10.1016/j.molmed.2020.01.012
10.18637/jss.v036.i03
10.1007/s13277-016-5001-6
10.1016/j.jtho.2018.09.022
10.3389/fonc.2018.00275
10.1016/j.mrfmmm.2015.05.002
10.1177/0300060519848924
10.1038/s41598-020-74494-y
10.1111/j.0006-341X.2000.00455.x
10.1186/1471-230X-11-11
10.1038/s41416-022-02017-9
10.1016/j.jamcollsurg.2014.03.062
10.1177/1758835920962966
10.1186/s12907-018-0079-y
10.1007/s10120-022-01331-8
10.1038/nature13480
10.1186/s13148-019-0747-5
10.1016/j.critrevonc.2020.103109
10.1186/1745-6215-8-16
10.1016/j.ebiom.2019.04.003
10.1515/cclm-2012-0320
10.1016/j.jmoldx.2020.04.210
10.1016/j.cgh.2019.07.045
10.1002/ijc.30620
10.1007/s10620-020-06710-8
10.5858/arpa.2013-0285-OA
10.2306/scienceasia1513-1874.2020.056
10.1001/jamanetworkopen.2021.18457
10.1038/s41467-020-17316-z
10.3389/fcell.2021.639233
ContentType Journal Article
Copyright 2023 Informa UK Limited, trading as Taylor & Francis Group 2023
Copyright_xml – notice: 2023 Informa UK Limited, trading as Taylor & Francis Group 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1080/1354750X.2023.2201664
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1366-5804
EndPage 436
ExternalDocumentID 37036017
10_1080_1354750X_2023_2201664
2201664
Genre Research Article
Meta-Analysis
Systematic Review
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
23N
36B
4.4
5GY
AAAVZ
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLKL
ABOCM
ABUPF
ABXYU
ACENM
ACGEJ
ACGFS
ACIEZ
ACUHS
ADCVX
ADRBQ
ADXPE
AECIN
AENEX
AEOZL
AFKVX
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJWEG
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
AMDAE
BABNJ
BLEHA
BOHLJ
CCCUG
COF
CS3
DKSSO
EAP
EBC
EBD
EBS
EMB
EMK
EMOBN
EPL
EST
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M4Z
O9-
P2P
RNANH
RVRKI
SV3
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TUS
UEQFS
UHWXJ
V1S
~1N
AAGDL
AAYXX
ABWVI
ADYSH
AFRVT
AMPGV
CITATION
53G
5VS
AALIY
AAORF
AAPXX
ABWCV
ABZEW
ACKZS
ACOPL
ACYZI
ADFOM
ADFZZ
AEIIZ
AFLEI
AJVHN
AWYRJ
BRMBE
CAG
CGR
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
EJD
JENTW
M44
NPM
NUSFT
OVD
QQXMO
TASJS
TEORI
7X8
ID FETCH-LOGICAL-c366t-b02fa59dd9a410b42b5036f70f9ef15903c33b7dd8e7b68783e80fd8bcbe7a4e3
ISSN 1354-750X
1366-5804
IngestDate Fri Jul 11 06:54:33 EDT 2025
Mon Jul 21 05:27:56 EDT 2025
Tue Jul 01 02:04:23 EDT 2025
Thu Apr 24 23:12:22 EDT 2025
Wed Dec 25 09:06:30 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords meta-analysis
Circulating tumour DNA
gastric cancer
prognosis
liquid biopsy
survival
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c366t-b02fa59dd9a410b42b5036f70f9ef15903c33b7dd8e7b68783e80fd8bcbe7a4e3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Undefined-1
content type line 23
ObjectType-Article-3
PMID 37036017
PQID 2799172981
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2799172981
informaworld_taylorfrancis_310_1080_1354750X_2023_2201664
pubmed_primary_37036017
crossref_primary_10_1080_1354750X_2023_2201664
crossref_citationtrail_10_1080_1354750X_2023_2201664
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-04
PublicationDateYYYYMMDD 2023-07-04
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-04
  day: 04
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biomarkers
PublicationTitleAlternate Biomarkers
PublicationYear 2023
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0072
CIT0071
CIT0030
CIT0074
CIT0073
CIT0032
CIT0076
CIT0031
CIT0075
CIT0034
CIT0078
CIT0033
CIT0077
CIT0070
CIT0036
CIT0035
CIT0079
CIT0038
Rawla P. (CIT0051) 2019; 14
CIT0039
CIT0041
CIT0040
CIT0043
CIT0042
CIT0001
CIT0045
CIT0044
Wang G. (CIT0065) 2015; 2015
Wu R. (CIT0068) 2020; 13
CIT0003
CIT0047
CIT0002
CIT0046
CIT0005
CIT0049
CIT0004
CIT0048
CIT0006
CIT0009
CIT0008
CIT0050
CIT0052
CIT0010
CIT0054
Căinap C. (CIT0007) 2015; 88
CIT0012
CIT0056
CIT0011
CIT0055
CIT0014
CIT0058
CIT0013
CIT0057
CIT0016
CIT0015
CIT0059
CIT0018
CIT0017
Wu Y.-C. (CIT0069) 2014; 7
CIT0019
Leon S. (CIT0037) 1977; 37
CIT0061
CIT0060
CIT0063
CIT0062
CIT0021
CIT0020
CIT0064
CIT0023
CIT0067
CIT0022
CIT0066
Schwarzer G. (CIT0053) 2007; 7
CIT0025
CIT0024
CIT0027
CIT0026
CIT0029
CIT0028
References_xml – ident: CIT0034
  doi: 10.1158/1078-0432.CCR-18-1128
– ident: CIT0027
  doi: 10.1016/j.aca.2020.02.006
– ident: CIT0031
  doi: 10.1186/s12943-020-01274-7
– ident: CIT0054
  doi: 10.1007/s10555-020-09925-3
– ident: CIT0071
  doi: 10.1038/nmat4997
– ident: CIT0079
  doi: 10.1002/cam4.2799
– ident: CIT0021
  doi: 10.7326/0003-4819-158-4-201302190-00009
– ident: CIT0024
  doi: 10.1136/bmj.327.7414.557
– volume: 7
  start-page: 40
  issue: 3
  year: 2007
  ident: CIT0053
  publication-title: R news
– ident: CIT0055
  doi: 10.1016/S0140-6736(20)31288-5
– ident: CIT0014
  doi: 10.1002/ijc.30018
– ident: CIT0020
  doi: 10.1136/bmjgast-2019-000355
– ident: CIT0025
  doi: 10.1002/jcla.23936
– ident: CIT0032
  doi: 10.1158/1078-0432.CCR-21-1414
– ident: CIT0017
  doi: 10.1016/j.annonc.2022.02.007
– ident: CIT0046
  doi: 10.1136/bmj.n71
– ident: CIT0003
  doi: 10.1259/bjr.20181044
– volume: 7
  start-page: 1553
  issue: 4
  year: 2014
  ident: CIT0069
  publication-title: International journal of clinical and experimental pathology
– ident: CIT0050
  doi: 10.7717/peerj.2112
– ident: CIT0022
  doi: 10.1186/1471-230X-13-87
– ident: CIT0033
  doi: 10.1177/1533033820973279
– ident: CIT0059
  doi: 10.1001/jama.283.15.2008
– ident: CIT0062
  doi: 10.1007/s10120-022-01313-w
– ident: CIT0029
  doi: 10.1007/s10620-007-0135-4
– ident: CIT0041
  doi: 10.1371/journal.pone.0067195
– ident: CIT0018
  doi: 10.18632/oncotarget.14064
– ident: CIT0030
  doi: 10.1007/s10238-010-0097-2
– ident: CIT0039
  doi: 10.5230/jgc.2013.13.3.157
– ident: CIT0043
  doi: 10.1136/bmj.b2535
– ident: CIT0077
  doi: 10.5152/tjg.2021.20832
– ident: CIT0005
  doi: 10.1371/journal.pone.0242145
– ident: CIT0070
  doi: 10.1186/s12967-022-03567-5
– ident: CIT0013
  doi: 10.1136/bmj.315.7109.629
– ident: CIT0004
  doi: 10.1080/10408363.2019.1700902
– ident: CIT0047
  doi: 10.1001/jama.2016.7914
– ident: CIT0056
  doi: 10.1136/gutjnl-2020-322658
– ident: CIT0038
  doi: 10.1007/s12253-019-00658-5
– ident: CIT0064
  doi: 10.1002/jrsm.11
– ident: CIT0075
  doi: 10.1038/s41419-020-2531-z
– ident: CIT0036
  doi: 10.1038/s41467-020-14310-3
– ident: CIT0019
  doi: 10.1007/s10620-013-3007-0
– ident: CIT0042
  doi: 10.1158/1078-0432.CCR-19-1704
– ident: CIT0045
  doi: 10.1038/s41416-020-1002-8
– ident: CIT0048
  doi: 10.3390/genes10110926
– volume: 14
  start-page: 26
  issue: 1
  year: 2019
  ident: CIT0051
  publication-title: Przeglad gastroenterologiczny
– ident: CIT0023
  doi: 10.1016/j.molmed.2020.01.012
– ident: CIT0063
  doi: 10.18637/jss.v036.i03
– ident: CIT0072
  doi: 10.1007/s13277-016-5001-6
– ident: CIT0008
  doi: 10.1016/j.jtho.2018.09.022
– ident: CIT0052
  doi: 10.3389/fonc.2018.00275
– ident: CIT0002
  doi: 10.1016/j.mrfmmm.2015.05.002
– ident: CIT0026
  doi: 10.1177/0300060519848924
– ident: CIT0035
  doi: 10.1038/s41598-020-74494-y
– ident: CIT0012
  doi: 10.1111/j.0006-341X.2000.00455.x
– ident: CIT0044
  doi: 10.1186/1471-230X-11-11
– ident: CIT0016
  doi: 10.1038/s41416-022-02017-9
– ident: CIT0058
  doi: 10.1016/j.jamcollsurg.2014.03.062
– ident: CIT0057
  doi: 10.1177/1758835920962966
– volume: 2015
  start-page: 1
  year: 2015
  ident: CIT0065
  publication-title: Biomed research international
– ident: CIT0011
  doi: 10.1186/s12907-018-0079-y
– ident: CIT0028
  doi: 10.1007/s10120-022-01331-8
– ident: CIT0010
  doi: 10.1038/nature13480
– ident: CIT0015
  doi: 10.1186/s13148-019-0747-5
– ident: CIT0049
  doi: 10.1016/j.critrevonc.2020.103109
– ident: CIT0061
  doi: 10.1186/1745-6215-8-16
– ident: CIT0066
  doi: 10.1016/j.ebiom.2019.04.003
– volume: 37
  start-page: 646
  issue: 3
  year: 1977
  ident: CIT0037
  publication-title: Cancer research
– ident: CIT0001
  doi: 10.1515/cclm-2012-0320
– ident: CIT0006
  doi: 10.1016/j.jmoldx.2020.04.210
– ident: CIT0060
  doi: 10.1016/j.cgh.2019.07.045
– volume: 13
  start-page: 203
  issue: 2
  year: 2020
  ident: CIT0068
  publication-title: International journal of clinical and experimental pathology
– ident: CIT0076
  doi: 10.1002/ijc.30620
– ident: CIT0073
  doi: 10.1007/s10620-020-06710-8
– ident: CIT0078
  doi: 10.5858/arpa.2013-0285-OA
– ident: CIT0040
  doi: 10.2306/scienceasia1513-1874.2020.056
– ident: CIT0067
  doi: 10.1001/jamanetworkopen.2021.18457
– volume: 88
  start-page: 111
  issue: 2
  year: 2015
  ident: CIT0007
  publication-title: Clujul medical (1957)
– ident: CIT0009
  doi: 10.1038/s41467-020-17316-z
– ident: CIT0074
  doi: 10.3389/fcell.2021.639233
SSID ssj0013298
Score 2.3722858
SecondaryResourceType review_article
Snippet Background: Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in...
Circulating tumour DNA (ctDNA) has demonstrated robust diagnostic accuracy in several digestive cancers. However, the prognostic role of ctCDNA in gastric...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 427
SubjectTerms Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Circulating Tumor DNA - genetics
Circulating tumour DNA
Disease-Free Survival
gastric cancer
Humans
liquid biopsy
meta-analysis
Prognosis
Stomach Neoplasms - diagnosis
Stomach Neoplasms - genetics
survival
Title Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis
URI https://www.tandfonline.com/doi/abs/10.1080/1354750X.2023.2201664
https://www.ncbi.nlm.nih.gov/pubmed/37036017
https://www.proquest.com/docview/2799172981
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLegE4jLBANGx4eMxA2lJLbzxa1jqyZoy6WVugOKbMfZIm0J6pID--t5jt0kFUUbXKLKshvX79fn9_0Q-kB46rpKuE5IWOYw4imHp9pTSFO4YWOWCa6Tk2fz4GzJvq78VdeMs8kuqcRI3u7MK_kfqsIY0FVnyf4DZdsvhQH4DPSFJ1AYnvei8bLKr_LbJm02X8umEZdOfqpBnV9_PJmPdRMZ3oRgFaWux6wrAqS5NtNrGfGC654dUsd9SbU2Wc_XquIOt4VKthy-eXmtI3k658_MVB-YAr4uuiABm-sB-7isW45_Xjd2V5Vflt3cc2up_qb6lgdCmyhV1mOWNAgcP7JDaseY5bAk6iHJ77FLZuoC_MHGTdyjR30GAs1qpF8-IiCqBAHr7q2Nr37-PZksp9NkcbpaPER7BPQFMkB74-OT40nPodS0RW63t0nmitxPO1-zJaZsFbH9uyrSiCSLp2jf6hJ4bIDxDD1QxQF6ZLqL_jpAj2c2buI5-tEiBfeQgg1SMCAF8xvMcYcU3CIFlxm2SMEGKZ9h5hZOXqDl5HTx5cyxjTUcCb-_coRLMu7HaRpz5rmCEeGDIJOFbharDORbl0pKRZimkQpFEIURVZGbpZGQQoWcKfoSDYqyUK8QlkEGk0HmdAOQcygT-g6QLAY1lMvQS4eIbc4xkbbqvG5-cpV4tjjt5vgTffyJPf4hGrXLfpqyK3ctiPtESqrG3pWZ5jQJvWPt-w1FE2Cu2mPGC1XWNwkJQX0C9TPyhujQkLrdDtWl6-A-O7rH6tfoSfcHeoMG1bpWb0GYrcQ7C9TfKzCX1w
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utilizing+circulating+tumour+DNA+as+a+prognostic+predictor+of+gastric+cancer%3A+a+meta-analysis&rft.jtitle=Biomarkers&rft.au=Min%2C+Liang&rft.au=Chen%2C+Jinghua&rft.au=Yu%2C+Meihong&rft.au=Yang%2C+Ke&rft.date=2023-07-04&rft.issn=1366-5804&rft.eissn=1366-5804&rft.volume=28&rft.issue=5&rft.spage=427&rft_id=info:doi/10.1080%2F1354750X.2023.2201664&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1354-750X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1354-750X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1354-750X&client=summon